CURRENT NEWS

Doctors troubled by rise of lung cancer in non-smokers
CTV News
Lung cancer remains the single biggest cause of cancer death in Canada, accounting for a staggering quarter of all cancer deaths.
Read More
More research funding needed to quell lung cancer mortality rates
The Globe and Mail
Lung cancer causes 27 percent of cancer deaths among Canadians. This year alone, Statistics Canada estimates that there will be 25, 400 new cases of lung cancer diagnosed.
Read More
Lung Cancer is a Women's Disease Too
Raising money for "women’s cancers” made the event more distinctive while also broadening its appeal. In addition to breast cancer, funds now go to research into for five gynecological cancers: ovarian, cervical, uterine, vaginal and vulvar.
Read More
 

Home > Lung Cancer > Clinical Trials > Current Clinical Trials > Symptomatic Therapy Trials
Print this page Tell A Friend Add to Favorites

Symptomatic Therapy Trials

1. Systemic and Topical Treatments for Rash Secondary to Erlotinib in Lung Cancer (LUTRAERL)

ClinicalTrials.gov Identifier: NCT00473083

The purpose of this trial is to determine if rash caused by erlotinib can be successfully treated and if so to determine the optimal treatment approach.

BC
BCCA, Vancouver
BCCA, Vancouver Island
BCCA, Fraser Valley

 
 

Quick Links

  • Privacy Policy
    •   
  • Site Map
    •   
  • Sign Up for Our Newsletter
    •   
  • Board Members

    • CONTACT INFORMATION

    Lung Cancer Canada
    1896-A Avenue Road
    Toronto, Ontario
    M5M 3Z8




    info@lungcancercanada.ca
    Telephone: 416-785-3439
    Toll Free: 1-888-445-4403
    Fax: 416-785-2905

    Site by Inorbital